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Abstract 
 
Background:  ICD/BVP  indications  are  expanding.  They  are 
expensive devices and historically, morbidities associated with 
their use were high. The starting experience at the Gold Coast 
Hospital is being reviewed. 
 
Methods:  A  retrospective  chart  review  of  all  the  ICD/BVPs 
implanted  in  the  Gold  Coast  Hospital  from  06/07/2007  – 
17/06/2008, with special emphasis on device indications and 
complications.  
 
Results:  Devices  implanted  were  (31).  Primary  prevention 
devices  (67%),  secondary  prevention  devices  (33%). 
Indications  were;  Non-ischemic  Dilated  Cardiomyopathy 
(35%),  Out-of-hospital  Cardiac  Arrest  (26%),  Conscious  VT 
(13%),  Ischemic  Dilated  Cardiomyopathy  (10%),  In-hospital 
Cardiac  Arrest  (6%),  Long-QT  Syndrome  (6%)  and 
Catecholamine-related  Polymorphic  VT  (3%).  Major 
complications reported; lung contusion (1), left haemothorax 
(1),  failed  coronary  sinus  lead  positioning  (2),  lead  re-
positioning  (2),  atrial  lead  removal  (1),  left  subclavian  vein 
thrombosis (1), lead malfunction leading to VT under sensing 
and  syncope  (1).  Device-administered  therapies  were  eight; 
Inappropriate  discharges  (5),  Appropriate  discharges  (1), 
successful Anti-tachycardia Pacing (2).  
 
Conclusions:  We  believe  that  ICDs  are  very  effective  life-
saving devices but unfortunately they still are very expensive 
and their use can be associated with significant morbidities 
especially during the learning curve. 
 
 
 
Introduction 
ICDs are very effective in the secondary prevention of sudden 
cardiac  death;  their  effectiveness  over  placebo  and  anti-
arrhythmic  drugs  has  been  demonstrated  in  major  multi-
centre  randomised  controlled  trials  (6,  7,  8,  and  9).  The 
indications for the implantation of ICDs have quickly expanded 
from  the  secondary  prevention  of  sudden  cardiac  death  in 
persons who suffered a VT/ VF cardiac arrest to be used 
more in the primary prevention of sudden cardiac death 
in persons at risk of arrhythmic cardiac death after their 
effectiveness was shown in big trials (6,10,11,12,13) the 
factor  which  had  the  largest  impact  on  the  increase  in 
their use in recent years, the benefit is claimed to be a 
20–30% relative reduction in mortality at one year, which 
is maintained over 3–5 years of follow-up, the absolute 
mortality  benefit  was  approximately  1–3%  per  year 
compared  to  standard  medical  treatment  (1).  BVPs  is 
another  area  of  device  therapy  which  is  quickly 
developing;  BVPs  reduce  symptoms  and  frequency  of 
hospitalisation  when  carried  out  in  patients  with 
symptomatic dilated CHF and prolonged QRS duration. A 
recent study has also demonstrated a mortality benefit of 
BVPs in patients with heart failure (1, 13). We wanted to 
present our own registry in the first year of our institute’s 
experience with ICD/BVPs implantation, looking mainly at 
the implantation indications and all complications that we 
could trace. 
 
Methods 
A list of all ICDs and BVPs was taken from the catheter 
laboratory at the Gold Coast Hospital from the start of the 
program with the first ICD implanted on 6
th July 2007 till 
the end of analysis period on the 17
th July 2008 which 
included  a  total  of  thirty  one  devices,  charts  were 
requested and reviewed. Excel tables were created with 
the  patients’  characteristics,  device  indications,  device 
type  by  function,  device  manufacturer,  device  cost, 
procedure time, hospital stay, use of antibiotics, use of 
chest  x-ray  to  check  for  device  position  and  procedure 
complication, device check by manufacturer, documented 
immediate  complications,  follow  up  including  all  device 
related  re-admissions,  device  check-up  and  all 
adjustments,  referrals  to  another  institute  and  their 
outcomes. 
 
Results 
A total of 31 devices in 31 patients were implanted (25 
male, 6 female), Mean patient’s age was 58 years (20-75 
years), and mean follow-up period was 9 months (3-15 
months).  Primary  prevention  devices  were  21  (67%), 
secondary  prevention  devices  were  10  (33%),  the 
commonest  single  indication  in  our  series  was  non-
ischemic dilated cardiomyopathy (11 patients 35%), the 
second  most  common  indication  was  out-of-hospital 
cardiac arrest which occurred in 8 patients (26%) while 
conscious VT was next (4 patients 13%), ischemic dilated 
cardiomyopathy 3 patients (10%), 2 patients (6%) had in-
hospital-cardiac arrest, 2 patients had congenital long QT 
syndrome (6%) and 1 patient had catecholamine-related 
polymorphic VT (3%), table (1) . 
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For patient’s characteristics, co-morbidities and medications 
refer to tables (2, 3, 4) 
 
21 devices (70%) were single chamber ICDs with a single right 
ventricular  sensing  pacing  and  defibrillating  lead,  4  devices 
(13%)  were  double  chamber  ICDs  with  an  additional  atrial 
sensing and pacing lead as well, 5 devices (16%) were BVPs 
with  the  addition  of  a  coronary  sinus  lead  to  the  double 
chamber ICD to pace the left ventricle to achieve cardiac re-
synchronization function and finally, one patient had an ICD 
pulse generator replaced only (because of battery run out). 
 
Devices  manufacturers  were;  St.  Jude  Medical  17  devices 
(55%),  Medtronic  11  devices  (35%)  and  Guidant  3  devices 
(10%).  
 
All devices were implanted subcutaneously in the left pectoral 
area; all patients had prophylactic antibiotics intra-operatively 
with intra-venous Cephazolin plus intra-venous Gentamycin in 
selected patients. All patients had prophylactic oral antibiotics 
with Cephalexin for 5 days post-procedure. All patients in our 
series had a check chest X-ray the first post-procedure day, all 
devices were checked by manufacturer, all patients had device 
check at 6 weeks and then at 6 monthly intervals thereafter 
except one patient. 
 
The  majority  of  the  devices  were  implanted  in  a  day 
procedure, 18 (58%), 8 patients (26%) had a hospital stay from 
2-7 days, of them 3 patients had a conscious VT within the 
same hospital admission and 5 patients (16%) had a hospital 
stay  of  more  than  7  days  all  of  them  had  a  cardiac  arrest 
within the same hospital admission and a prolonged intensive 
care unit stay prior to the implantation procedure. Procedure 
duration was properly documented in 25 patients  (80%), in 
the majority it was less than 90 minutes (17 procedures 54%), 
only 4 (13%) procedures lasted longer than 180 minutes and 
they were all BVPs. 
 
Twenty one patients (67%) in our series had reported some 
complications,  ten  had  reported  none,  and  around  thirty 
complication  occurrences  were  documented.  These  were 
procedure related or device related. Procedural complications 
were;  significant  pain  requiring  narcotic  analgesics  in  six 
patients, significant bleeding from implantation wound which 
required  local  pressure  in  two  patients  plus  intra-venous 
desmopressin infusion in one patient, local hematoma in one 
patient  which  happened  on  the  8
th    post-procedure  day 
secondary  to  minor  trauma,  minor  haemoptysis  on  the  3
rd  
post-procedure  day  in  one  patient  (CT  scan  of  the  chest 
confirmed lung contusion which was managed conservatively) 
and one patient was admitted with left sided haemothorax on 
the 14
th post-procedure day despite the fact that chest X-ray 
taken on the 1
st post-procedure day was normal, required two 
inter-costal  chest  drains  and  video-assisted  thoracoscopic 
procedure to stop the bleeding, two patients failed coronary 
sinus lead positioning for BVP, one patient eventually had an 
epicardial  lead  placed  on  mini-thoracotomy  at  another 
hospital to achieve BV pacing, the other was changed to single 
chamber ICD mode and the atrial lead was retrieved at a later 
date  because  that  patient  developed  atrial  fibrillation  and 
failed  cardio-version,  one  patient  developed  left  subclavian 
vein  thrombosis  on  the  10
th  post-procedure  day,  one 
patient developed persistent left shoulder and ICD pocket 
pain and was referred to another hospital to consider sub-
muscular implantation of the ICD. 
 
As  far  as  the  device  complications  are  concerned, 
Inappropriate discharges occurred in four patients, in the 
first  patient  it  was  for  a  supraventricular  tachycardia 
falling in the VT detection zone for that the ICD was re-
programmed,  in  the  second  patient  it  was  for  a  non-
sustained  VT  after  anti-tachycardia  pacing  mode  failure 
secondary to under-rate detection for which ICD was re-
programmed but inappropriate discharge recurred for a 
non-sustained VT as well which failed to respond to anti-
tachycardia pacing therapy appropriately delivered by the 
device  this  patient  was  started  on  treatment  with 
amiodarone to suppress the non-sustained VTs, in a third 
patient  it  was  for  an  atrial  flutter  falling  in  the  VT 
detection zone in whom a trial of radiofrequency catheter 
ablation of the atrial flutter was attempted but failed and 
both atrial flutter and inappropriate discharge of the ICD 
recurred, the patient was eventually referred to another 
hospital to attempt atrial flutter ablation with a thermo-
cool catheter and 3D mapping, and in the last patient it 
was  for  over-sensing  noise  caused  by  ICD  pocket 
manipulation, in this patient the right ventricular lead was 
unscrewed and re-inserted at the ICD pocket. One patient 
received  an  appropriate  discharge  which  was  for  VF 
properly  sensed  and  terminated.  Other  therapies 
administered  were  anti-tachycardia  pacing  which 
successfully terminated sustained VT in two patients. 
 
Lead  related  complications  occurred  in  five  patients; 
coronary  sinus  lead  needed  to  be  repositioned  in  one 
patient because of diaphragmatic stimulation on the 22
nd 
post-implantation  day,  right  ventricular  lead  had  to  be 
repositioned into right ventricular   apex in one patient on 
the 5
th post-implantation day as was under-sensing, atrial 
lead had to be removed on the 10
th post-implantation day 
in  one  patient  as  it  was  not  in  place  and  the  patient 
developed atrial fibrillation which persisted after a trial of 
electric  cardio-version,  right  ventricular  lead  had  to  be 
repositioned in one patient because of high threshold on 
the  29
th  post-implantation  day  and  lastly  one  patient 
needed  a  special  right  ventricular  lead  to  replace  the 
original  lead  which  was  done  in  a  different  hospital 
because of VT un-detection leading to a syncopal event 
which happened on day 144 post-implantation. 44 of re-
admission days directly related to ICD problems happened 
because of these complications, and a total of 4 patients 
had to be referred to another institute to deal with these 
complications  as  outlined  above  as  our  institute  lacked 
the  technology  or  the  personnel  to  deal  with  those 
complications.  For  a  summary  of  device  complication 
refer to (table-5). 
 
Discussion 
ICD/BVPs  are  very  effective  life-saving  devices  that  are 
also very costly which is an important limitation to their 
use;  device  only  cost  in  our  registry  was  425950 
Australian Dollars. In addition their use can be associated  Australasian Medical Journal 2010, 1, 1, 23-27 
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with a lot of complications that can affect patients’ quality of 
life  quite  adversely;  these  complications  make  the  second 
important  limitation  to  the  expansion  in  their  use.  The 
incidence of ICD complications is difficult to determine due to 
inconsistent definitions and the lack of mandatory reporting. 
Information comes from annual reports filed with the United 
States Food and Drug Administration, by companies that make 
devices and from voluntary registries (2). Approximately 50% 
of patients experience an adverse event within the first year 
after ICD implantation (2, 3). The rate of freedom from any 
adverse  event  at  1,  3,  and  12  months  was  79,  68,  and  51 
percent, respectively as was illustrated in a prospective study 
of 778 patients receiving a trans-venous ICD (2,3). Among the 
complications  that  occurred,  60  %  were  due  to  the  ICD 
system, 29 % were related to the implantation procedure and 
11  %  were  not  device-related  (2).  As  far  as  procedural 
complications are concerned, a peri-procedural mortality of 0-
0.8 % has been reported (2), incidence of severe bleeding was 
1.5%, and infection of the generator pocket or leads has been 
reported  in  up  to  7%.  ICD  system  problems  included  lead 
failure; the estimated lead survival rates at 5 and 8 years are 
85% and 60% respectively. The annual defect rate increases 
with time and reaches 20% in 10-year-old leads (5) mainly due 
to lead dislodgement, fracture, and insulation defects (2, 5). 
The other common complication is inappropriate shocks which 
occurred  in  20-25%  of  ICD  patients  the  main  cause  being 
supra-ventricular  tachy-arrhythmias  including  sinus 
tachycardia, atrial fibrillation, and the other important cause is 
non-sustained VT (2).  
 
In  conclusion,  we  believe  that  ICDs  are  very  effective  life-
saving devices but unfortunately they still are very expensive 
and their use can be associated with significant morbidities 
especially  during  the  learning  curve.  We  appreciate  the 
limitation  of  our  data  and  that  generalisation  is  difficult 
because our sample size is quite small, and it early experience 
in  a  single  public  hospital  with  a  relatively  low  volume  of 
device implantation basically led by one cardiologist. But we 
believe that it represents the experience of many programs on 
a learning curve and we present our experience to help those 
planning to start a similar program.  
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TABLES 
 
Table (1) Number of patients for each device indication 
Device indication  Number of 
patients (%) 
Primary prevention of SCD 
     Ischemic DCM 
     Non-ischemic DCM 
     Conscious VT (LV scar tissue) 
     LQTS 
     CPVT 
 
Secondary prevention of SCD 
    Out-of-hospital cardiac arrest  
          Ischemic DCM 
          IHD ( LV scar tissue) 
          IHD ( LV aneurysm) 
          LQTS 
 
   In-hospital cardiac arrest  
         Ischemic DCM 
         IHD (LV aneurysm) 
21 (67%) 
3 (10%) 
11 (35%) 
4 (13%) 
2 (6%) 
1 (3%) 
 
10 (33%) 
8 (26%) 
3 (10%) 
3 (10%) 
1 (3%) 
1 (3%) 
 
2 (6%) 
1 (3%) 
1 (3%) 
Table  key  words:  SCD  (sudden  cardiac  death),  LV  (left 
ventricle), LQTS (long QT syndrome), CPVT (catechol-related 
polymorphic  VT),  DCM  (dilated  cardiomyopathy),  IHD 
(ischemic heart disease). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table (2) Patient characteristics 
Patient’s characteristics  Number of 
patients (%) 
Echocardiography: 
   Left ventricular dilatation 
   Significant left ventricular 
dilatation (LVEDD > 60 mm) 
   Reduced Left Ventricular EF (< 
50%) 
   Mild LVSD (EF 40-49%) 
   Moderate LVSD ( EF 30-39%) 
   Severe LVSD ( EF < 30%) 
   Regional wall motion 
abnormality (hypo/akinesia) 
   Global left ventricular 
hypokinesis 
 
Coronary angiography: 
   Normal coronaries 
   Stable coronary artery disease 
(no intervention) 
   Coronary artery disease 
requiring intervention (stent) 
 
Electrocardiography: 
   Rhythm  
   Sinus 
   Atrial Fibrillation/ Flutter  
   Pathological Q- waves 
   Wide QRS complex 
   LBBB pattern 
   RBBB pattern 
   NIVCD pattern 
   Non-specific T wave changes 
 
22 (70%) 
13 (60%) 
26 (83%) 
6 (23%) 
5 (19%) 
15 (58%) 
15 (50%) 
13 (42%) 
 
22 (71%) 
11 (50%) 
10 (32%) 
1 (3%) 
 
 
 
27 (87%) 
4 (13%) 
12 (38%) 
13 (42%) 
10 (32%) 
2 (6%) 
1 (3%) 
15 (48%) 
Table  key  word:  LVEDD  (left  ventricle  end-diastolic 
dimension), EF (ejection fraction), LVSD (left  ventricular 
systolic  dysfunction),  LBBB  (left  bundle  branch  block), 
RBBB  (right  bundle  branch  block),  NIVCD  (non-specific 
intra-ventricular conduction delay). 
  Australasian Medical Journal 2010, 1, 1, 23-27 
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Table (3) Patients’ co-morbidities 
Co-morbidities:  Number of 
patients ( %) 
 Ischemic heart disease: 
                Acute myocardial 
infarction history 
                CABG surgery 
                PCI/ stents 
 
Heart failure: 
                NYHA class 1-2 
                NYHA class 3-4  
 
Atrial Fibrillation/ Flutter: 
 
Diabetes Mellitus: 
 
Hypertension: 
 
Aortic valve replacement: 
 
Alcohol abuse: 
 
Dys-lipidemia: 
 
Cerebro-vascular accidents/ 
Transient ischemic attacks: 
 
Chronic obstructive airway 
disease: 
 
Thyroid disorders: 
              Hyperthyroidism 
              Hypothyroidism 
 
Chronic liver disease: 
 
Chronic renal failure: 
17(55%) 
11(33%) 
7 (22%) 
7 (22%) 
 
27 (78%) 
21 (77%) 
6 (23%) 
 
7 (22%) 
 
5 (16%) 
 
16 (51%) 
 
2 (6%) 
 
7 (22%) 
 
9 (29%) 
 
4 (13%) 
 
 
2 (6%) 
 
4 (13%) 
2 (6%) 
2 (6%) 
 
3 (10%) 
 
2 (6%) 
Table  key  words:  CABG  (coronary  artery  bypass  graft),  PCI 
(percutaneous coronary intervention), NYHA (New York Heart 
Association). 
 
Table (4) Medications taken by patients 
Medication   Number of 
patients (%) 
Beta- blockers 
       Carvedilol  
       Bisoprolol  
       Metoprolol 
       Atenolol 
       Sotalol  
 
Angiotensin Converting Enzyme 
Inhibitors /Angiotensin 2 
Antagonists 
 
Statins  
 
Aldosterone antagonists 
      Spironolactone 
      Epleronone  
 
anti-platelets/ anti-coagulants 
      Aspirin  
      Clopidogrel 
      Warfarin 
 
Amiodarone 
 
Diuretics  
      Frusemide  
      Thiazide 
 
Digoxine  
 
30 (96%) 
13 (42%) 
7 (22%) 
5 (16%) 
4 (13%) 
1 (3%) 
 
24 (77%) 
 
 
18 (58%) 
 
12 (38%) 
11 (35%) 
1 (3%) 
 
23 (74%) 
18 (58%) 
7 (22%) 
6 (19%) 
 
8 (25%) 
 
16 (52%) 
14 (45%) 
2 (6%) 
 
7 (22%) 
 
 
 
Table (5) Device Complications 
Complication  Number of 
patients 
Procedure related 
       Pain 
       Bleeding 
       Haematoma 
       Lung contusion 
       Haemothorax  
       Subclavian vein thrombosis 
       Failed coronary sinus lead positioning 
       Persistent shoulder and ICD pocket 
pain 
 
Device/ lead related 
       Inappropriate discharges 
       Coronary sinus lead repositioning 
       Right ventricular lead repositioning 
       Atrial lead removal 
       Right ventricular lead replacement 
 
 
6 
2 
1 
1 
1 
1 
2 
1 
 
 
4 
1 
2 
1 
1 
 